Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Quotas - 2016 > Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017

Quotas - 2016

[Federal Register Volume 81, Number 193 (Wednesday, October 5, 2016)]
[Notices]
[Pages 69079-69083]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23988]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-443F]

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final order.


SUMMARY: This final order establishes the initial 2017 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Effective October 5, 2016.

FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control Division, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Legal Authority

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the DEA pursuant to 28 CFR 0.100.

Background

The 2017 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine that may be manufactured in the United States in 2017 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine, but do not include imports of controlled substances for use in industrial processes.

On July 22, 2016, a notice titled "Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017" was published in the Federal Register. 81 FR 47821. This notice proposed the 2017 aggregate production quotas for each basic class of controlled substance listed in schedules I and II and the 2017 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 22, 2016.

Comments Received

Thirteen comments were received from five DEA-registered manufacturers and four non-DEA registered entities within the published comment period regarding 22 different schedule I and II controlled substances. The DEA received two comments from two non-DEA registered entities within the published comment period regarding the proposed assessment of annual needs for the list I chemical ephedrine (for sale). Commenters stated that the proposed aggregate production quotas for acetyl fentanyl, AH-7921, amphetamine (for conversion), amphetamine (for sale), beta-hydroxythiofentanyl, butyryl fentanyl, cocaine, codeine (for conversion), codeine (for sale), dihydrocodeine, ecgonine, hydrocodone (for sale), hydromorphone, levorphanol, lisdexamfetamine, marihuana, meperidine, methylphenidate, nabilone, opium tincture, oxycodone (for sale), and sufentanil, as well as, the proposed assessment of annual needs for ephedrine (for sale) were insufficient to provide for the estimated medical, scientific, research, and industrial needs

[[Page 69080]]

of the United States, export requirements, and the establishment and maintenance of reserve stocks.

The DEA received one comment from a DEA-registrant and three comments by non-DEA registered entities regarding the proposed removal of the additional 25% of the estimated medical, scientific, and research needs for the United States. Two of the commenters requested that the DEA continue to include the additional 25%, one commenter requested transparency in the process of setting aggregate production quotas, and the last commenter agreed with the DEA that the additional 25% should not be included in aggregate production quotas values. The DEA has considered these comments, as well as the ones for specific controlled substances and ephedrine (for sale), in establishing the 2017 aggregate production quotas and assessment of annual needs.

Determination of 2017 Aggregate Production Quotas and Assessment of Annual Needs

In determining the 2017 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth in 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the 2016 manufacturing quotas, current 2016 sales and inventories, anticipated 2017 export requirements, industrial use, and additional applications for 2017 quotas, as well as information on research and product development requirements. Based on this information, the DEA has removed the additional 25% from the aggregate production quotas before determining that adjustments to the proposed aggregate production quotas for 4-anilino-n-phenethyl-piperidine, amphetamine (for conversion), amphetamine (for sale), cocaine, dihydrocodeine, ecgonine, etorphine hydrochloride, hydromorphone, levorphanol, lysergic acid dimethylamide, nabilone, opium tincture, and oripavine are warranted. Adjustment to the proposed annual assessment of needs for ephedrine (for sale) was also determined to be warranted. This final order reflects those adjustments.

Regarding acetyl fentanyl, AH-7921, beta-hydroxythiofentanyl, butyryl fentanyl, codeine (for conversion), codeine (for sale), hydrocodone (for sale), lisdexamfetamine, marihuana, meperidine, methylphenidate, oxycodone (for sale), and sufentanil, the DEA has determined that the proposed aggregate production quotas are sufficient to provide for the 2017 estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. This final order establishes these aggregate production quotas at the same amounts as proposed.

In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Administrator hereby establishes the 2017 aggregate production quotas for the following schedule I and II controlled substances and the 2017 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic Class 2017
Established Quotas
(g)
Schedule I
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) 15
1-(1-Phenylcyclohexyl)pyrrolidine 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 30
1-[1-(2-Thienyl)cyclohexyl]piperidine 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) 35
1-Benzylpiperazine 25
1-Butyl-3-(1-naphthoyl)indole (JWH-073) 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) 45
1-Hexyl-3-(1-naphthoyl)indole (JWH-019) 45
1-Methyl-4-phenyl-4-propionoxypiperidine 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) 35
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) 30
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) 30
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) 30
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) 30
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) 30
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 25
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 5
2,5-Dimethoxy-4-ethylamphetamine (DOET) 25
2,5-Dimethoxy-4-n-propylthiophenethylamine 25
2,5-Dimethoxyamphetamine 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 30
3,4,5-Trimethoxyamphetamine 25
3,4-Methylenedioxyamphetamine (MDA) 55
3,4-Methylenedioxymethamphetamine (MDMA) 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 40
3,4-Methylenedioxy-N-methylcathinone (methylone) 40
3,4-Methylenedioxypyrovalerone (MDPV) 35
3-FMC; 3-Fluoro-N-methylcathinone 25
3-Methylfentanyl 2
3-Methylthiofentanyl 2
4-Bromo-2,5-dimethoxyamphetamine (DOB) 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 25
4-FMC; Flephedrone 25
4-Methoxyamphetamine 150
4-Methyl-2,5-dimethoxyamphetamine (DOM) 25
4-Methylaminorex 25
4-MEC; 4-Methyl-N-ethylcathinone 25
4-Methyl-N-methylcathinone (mephedrone) 45
4-Methyl-α-pyrrolidinopropiophenone (4-MePPP) 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 50
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40
5-Fluoro-UR144, XLR11 25
5-Methoxy-3,4-methylenedioxyamphetamine 25
5-Methoxy-N,N-diisopropyltryptamine 25
5-Methoxy-N,N-dimethyltryptamine 25
AB-PINACA 15
Acetyl-alpha-methylfentanyl 2
Acetyldihydrocodeine 2
Acetylmethadol 2
AH-7921 30
Allylprodine 2
alpha-Ethyltryptamine 25
alpha-Methylfentanyl 2
alpha-Methylthiofentanyl 2
alpha-Methyltryptamine (AMT) 25
alpha-Pyrrolidinobutiophenone (α-PBP) 25
alpha-Pyrrolidinopentiophenone (α-PVP) 25
Alphacetylmethadol 2
Alphameprodine 2
Alphamethadol 2
Aminorex 25
APINCA, AKB48 25
Benzylmorphine 2
beta-Hydroxy-3-methylfentanyl 2
beta-Hydroxyfentanyl 2
beta-Hydroxythiofentanyl 30
Betacetylmethadol 2
Betameprodine 2
Betamethadol 4
Betaprodine 2
Bufotenine 3
Butylone 25
Butyryl fentanyl 30
Cathinone 24
Codeine methylbromide 5
Codeine-N-oxide 305
Desomorphine 25
Diethyltryptamine 25
Difenoxin 8,750
Dihydromorphine 1,566,000
Dimethyltryptamine 35
Dipipanone 5
Fenethylline 5
gamma-Hydroxybutyric acid 56,200,000
Heroin 25
Hydromorphinol 2
Hydroxypethidine 2
Ibogaine 5
Lysergic acid diethylamide (LSD) 15
Marihuana 472,000
Mescaline 25
Methaqualone 10
Methcathinone 25
Methyldesorphine 5
Methyldihydromorphine 2
Morphine methylbromide 5
Morphine methylsulfonate 5
Morphine-N-oxide 350
N,N-Dimethylamphetamine 25
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) 50
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) 50
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) 15
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl) 100
N-Ethyl-1-phenylcyclohexylamine 5
N-Ethylamphetamine 24
N-Hydroxy-3,4-methylenedioxyamphetamine 24
Naphyrone 25
Noracymethadol 2
Norlevorphanol 52
Normethadone 2
Normorphine 40
Para-fluorofentanyl 5
Parahexyl 5
Pentedrone 25
Pentylone 25
Phenomorphan 2
Pholcodine 5
Psilocybin 30
Psilocyn 50
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) 20
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) 20
Tetrahydrocannabinols 409,000
Thiofentanyl 2
Tilidine 25
Trimeperidine 2
UR-144 25
Schedule II
1-Phenylcyclohexylamine 4
1-Piperidinocyclohexanecarbonitrile 4
4-Anilino-N-phenethyl-4-piperidine (ANPP) 1,750,000
Alfentanil 4,200
Alphaprodine 2
Amobarbital 20,100
Amphetamine (for conversion) 12,000,000
Amphetamine (for sale) 42,400,000
Carfentanil 10
Cocaine 103,400
Codeine (for conversion) 40,000,000
Codeine (for sale) 45,000,000
Dextropropoxyphene 15
Dihydrocodeine 281,100
Dihydroetorphine 2
Diphenoxylate (for conversion) 15,000
Diphenoxylate (for sale) 820,000
Ecgonine 99,000
Ethylmorphine 2
Etorphine hydrochloride 32
Fentanyl 1,750,000
Glutethimide 2
Hydrocodone (for conversion) 122,000
Hydrocodone (for sale) 58,410,000
Hydromorphone 5,140,800
Isomethadone 4
Levo-alphacetylmethadol (LAAM) 3
Levomethorphan 10
Levorphanol 8,300
Lisdexamfetamine 19,000,000
Meperidine 3,706,000
Meperidine Intermediate-A 5
Meperidine Intermediate-B 9
Meperidine Intermediate-C 5
Metazocine 15
Methadone (for sale) 23,700,000
Methadone Intermediate 25,600,000
Methamphetamine 1,539,100
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)]
Methylphenidate 73,000,000
Morphine (for conversion) 27,300,000
Morphine (for sale) 41,000,000
Nabilone 19,000
Noroxymorphone (for conversion) 17,700,000
Noroxymorphone (for sale) 400,000
Opium (powder) 90,000
Opium (tincture) 907,200
Oripavine 22,000,000
Oxycodone (for conversion) 2,610,000
Oxycodone (for sale) 108,510,000
Oxymorphone (for conversion) 22,300,000
Oxymorphone (for sale) 4,200,000
Pentobarbital 27,500,000
Phenazocine 5
Phencyclidine 20
Phenmetrazine 2
Phenylacetone 20
Racemethorphan 2
Racemorphan 2
Remifentanil 3,000
Secobarbital 172,002
Sufentanil 4,000
Tapentadol 21,000,000
Thebaine 100,000,000
List I Chemicals
Ephedrine (for conversion) 50,000
Ephedrine (for sale) 5,360,000
Phenylpropanolamine (for conversion) 15,000,000
Phenylpropanolamine (for sale) 8,500,000
Pseudoephedrine (for conversion) 40
Pseudoephedrine (for sale) 200,000,000

[[Page 69083]]

The Administrator also establishes aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2017 aggregate production quotas and assessment of annual needs as needed.

Dated: September 26, 2016.

Chuck Rosenberg,
Acting Administrator.

[FR Doc. 2016-23988 Filed 10-4-16; 8:45 am]

BILLING CODE 4410-09-P

 

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Printing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility